NewsBenzingaMerck’s Phase 3 KEYNOTE-C93 Trial Meets Primary Endpoint Of Progression-Free Survival, Reducing Risk Of Progression Or Death By 43% With KEYTRUDA Monotherapy vs. Platinum Doublet Chemotherapy In dMMR Advanced Or Recurrent Endometrial Cancer Merck’s Phase 3 KEYNOTE-C93 Trial Meets Primary Endpoint Of Progression-Free Survival, Reducing Risk Of Progression Or Death By 43% With KEYTRUDA Monotherapy vs. Platinum Doublet Chemotherapy In dMMR Advanced Or Recurrent Endometrial Cancer Benzinga 2026.10.26 15:36 (GMT+0) Open on Benzinga Other news Citigroup Maintains Buy on Weatherford International, Lowers Price Target to $110 SpaceX Locks Up $40 Billion for AI Chips as Musk Warns Most Neoclouds Will Die Citigroup Maintains Buy on Liberty Energy, Raises Price Target to $28 Landmark Bancorp Declares 5% Stock Dividend Citigroup Maintains Neutral on Netstreit, Lowers Price Target to $18.5 Advance Auto Parts Turnaround Gains Traction, but Analysts Still See Execution Risks
